Making the most of the host

Although recent attention in the HCV space has focused on positive FDA panel recommendations for the protease inhibitors telaprevir and Victrelis

boceprevir from Vertex Pharmaceuticals Inc. and Merck & Co. Inc., respectively,¹ a French-led academic group has now uncovered targets on host cells that could also be inhibited to impede HCV entry.²...